Cellectar Biosciences (CLRB) Balance Sheet: Assets & Liabilities

Cellectar Biosciences (CLRB) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Cellectar Biosciences reported total assets of $14.98M and total liabilities of $6.44M. Shareholders' equity was $8.54M, down 40.3% from $14.29M a year earlier. Total debt stood at $409.59K against $13.20M in cash and short-term investments, a net cash position of $12.79M. That puts debt-to-equity at 0.05, compared with 0.03 a year earlier.

Cellectar Biosciences Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Cellectar Biosciences, Inc. (CLRB) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	13.20	23.29	9.56	19.87	35.70	57.17	10.61	13.26	10.01
Cash & Short-Term Investments	13.20	23.29	9.56	19.87	35.70	57.17	10.61	13.26	10.01
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.84	0.96	0.89	0.66	0.87	0.77	0.77	0.70	0.47
Total Current Assets	14.04	24.25	10.45	20.53	36.57	57.94	11.39	13.95	10.47
Non-Current Assets
Property, Plant & Equipment (Net)	0.91	1.19	1.59	0.98	0.55	0.64	0.78	0.54	0.24
Goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.68
Other Non-Current Assets	0.03	0.03	0.03	0.08	0.08	0.08	0.08	0.56	0.01
Total Non-Current Assets	0.94	1.22	1.62	1.06	0.63	0.72	0.87	1.10	1.93
Total Assets	14.98	25.47	12.08	21.59	37.20	58.66	12.25	15.05	12.87
Current Liabilities
Accounts Payable	1.44	4.11	9.18	2.56	1.42	1.43	1.28	1.54	1.87
Short-Term Debt	0.10	0.08	0.06	0.05	0.14	0.12	0.11	0.00	0.00
Accrued Liabilities	1.89	2.87	1.49	2.91	1.94	2.01	-	-	-
Other Current Liabilities	0.23	5.20	16.12	8.89	0.00	2.01	1.39	0.08	0.24
Total Current Liabilities	4.75	9.39	25.36	11.50	3.99	3.56	2.77	1.62	2.11
Non-Current Liabilities
Long-Term Debt	0.31	0.41	0.49	0.55	0.17	0.30	0.42	0.00	0.00
Other Non-Current Liabilities	0.00	1.38	0.00	0.00	0.00	0.00	0.00	0.17	0.00
Total Non-Current Liabilities	1.69	1.79	0.49	0.55	0.17	0.30	0.42	0.17	0.00
Total Liabilities	6.44	11.18	25.85	12.05	4.16	3.86	3.19	1.79	2.12
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-269.13	-247.34	-202.76	-159.99	-150.90	-126.78	-111.68	-97.59	-84.35
Additional Paid-in Capital	277.15	261.12	182.92	168.14	182.56	161.53	119.59	108.32	94.11
Shares Outstanding	4.24	1.54	0.69	0.31	0.20	-	-	-	-
Total Stockholders' Equity	8.54	14.29	-13.78	9.54	33.05	54.79	9.06	13.26	10.75
Total Liabilities & Equity	14.98	25.47	12.08	21.59	37.20	58.66	12.25	15.05	12.87

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cellectar Biosciences Balance Sheet

How much debt does Cellectar Biosciences have?

Cellectar Biosciences had total debt of $409.59K as of Dec 31, 2025, against $13.20M in cash and short-term investments. Its debt-to-equity ratio was 0.05. Total debt was $494.00K a year earlier.

What are Cellectar Biosciences's total assets?

Cellectar Biosciences reported total assets of $14.98M as of Dec 31, 2025, down 41.2% from $25.47M a year earlier. Total liabilities were $6.44M.

What is Cellectar Biosciences's shareholders' equity?

Cellectar Biosciences's shareholders' equity was $8.54M as of Dec 31, 2025, or about $2.01 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition